Patti G, et al. - In an attempt to describe the patient profile of someone who would get the most benefit from dual antiplatelet therapy (DAPT) following a non-cardioembolic, ischemic cerebrovascular event, researchers assessed DAPT vs single antiplatelet therapy (SAPT) in patients with stroke or transient ischemic attack (TIA) in this meta-regression analysis of 11 trials with 24,175 patients. Overall 12,074 patients were prescribed DAPT (aspirin plus clopidogrel) and 12,101 were treated with SAPT following a stroke or TIA event. Patients with stroke or TIA who have a higher baseline risk profile, greater stroke severity or concomitant carotid disease, who initiated DAPT in ≤7 days and took DAPT for ≤3 months were found to get the highest benefit from DAPT in this study.